Business Context and Reporting Period
P3 Health Partners Inc. filed a Form 8-K under Item 5.02 concerning changes in its finance leadership and related executive compensation arrangements. The earliest reported event was November 27, 2022; the filing was signed December 1, 2022.
Key Financial and Operating Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating performance metrics.
- Erin Darakjian, appointed Interim Chief Financial Officer effective November 1, 2022, remains Chief Accounting Officer, Senior Vice President, and principal accounting officer.
- Atul Kavthekar was appointed Chief Financial Officer and principal financial officer effective December 12, 2022.
Material Changes and Compensation Arrangements
- Ms. Darakjian will receive a $50,000 lump-sum payment in December 2022, a target annual bonus opportunity equal to 50% of base salary, and a 2022 bonus equal to 50% of base salary.
- Ms. Darakjian received an option to purchase 100,000 Class A common shares. Twenty-five percent vests October 18, 2023, with the remainder vesting in equal annual installments over the following three years, subject to continued employment.
- Mr. Kavthekar will receive an annual base salary of $450,000 and a target annual bonus equal to 50% of base salary.
- Mr. Kavthekar will receive a $50,000 signing bonus on the six-month anniversary of his effective date, subject to continued employment and pro-rata repayment if employment ends before the 18-month anniversary.
- Mr. Kavthekar will receive an option to purchase 600,000 Class A common shares. Twenty-five percent vests on the first anniversary of his effective date, with the remainder vesting in equal annual installments over the following three years, subject to continued employment.
- If terminated without cause, Mr. Kavthekar is entitled to six months of base salary, subject to execution and non-revocation of a general release and compliance with restrictive covenants.
Outlook, Risks, and Unusual Items
The filing does not provide formal financial guidance or an operating outlook. Key considerations include the transition to a new CFO, executive retention requirements tied to equity awards and signing compensation, potential dilution from options covering an aggregate of 700,000 shares, and the company’s obligation to provide severance if specified termination conditions are met.
Investor Verification Items
- Verify the effective date of Mr. Kavthekar’s appointment and the continued responsibilities of Ms. Darakjian.
- Review Exhibits 10.1 and 10.2 for complete compensation, vesting, repayment, severance, and restrictive-covenant terms.
- Assess the potential dilution from the 100,000-share and 600,000-share option grants.
- Review subsequent filings for updates to the CFO transition, compensation expense, and liquidity position.